Page 10«..9101112..2030..»

1st-of-its-kind therapy blocks immune attack after stem-cell transplant – Livescience.com

By daniellenierenberg

1st-of-its-kind therapy blocks immune attack after stem-cell transplant  Livescience.com

Continue reading here:
1st-of-its-kind therapy blocks immune attack after stem-cell transplant - Livescience.com

To Read More: 1st-of-its-kind therapy blocks immune attack after stem-cell transplant – Livescience.com
categoriaBone Marrow Stem Cells commentoComments Off on 1st-of-its-kind therapy blocks immune attack after stem-cell transplant – Livescience.com | dataJanuary 22nd, 2024
Read All

Implications of stress-induced gene expression for hematopoietic stem cell aging studies – Nature.com

By daniellenierenberg

Implications of stress-induced gene expression for hematopoietic stem cell aging studies  Nature.com

More:
Implications of stress-induced gene expression for hematopoietic stem cell aging studies - Nature.com

To Read More: Implications of stress-induced gene expression for hematopoietic stem cell aging studies – Nature.com
categoriaBone Marrow Stem Cells commentoComments Off on Implications of stress-induced gene expression for hematopoietic stem cell aging studies – Nature.com | dataJanuary 22nd, 2024
Read All

LVHN announces opening of new stem cell transplant center. Here’s what that means for the Lehigh Valley – The Morning Call

By daniellenierenberg

LVHN announces opening of new stem cell transplant center. Here's what that means for the Lehigh Valley  The Morning Call

Here is the original post:
LVHN announces opening of new stem cell transplant center. Here's what that means for the Lehigh Valley - The Morning Call

To Read More: LVHN announces opening of new stem cell transplant center. Here’s what that means for the Lehigh Valley – The Morning Call
categoriaBone Marrow Stem Cells commentoComments Off on LVHN announces opening of new stem cell transplant center. Here’s what that means for the Lehigh Valley – The Morning Call | dataJanuary 22nd, 2024
Read All

Fast Five Quiz: Chronic GVHD Risk Factors and Prevention – Medscape Reference

By daniellenierenberg

Fast Five Quiz: Chronic GVHD Risk Factors and Prevention  Medscape Reference

View original post here:
Fast Five Quiz: Chronic GVHD Risk Factors and Prevention - Medscape Reference

To Read More: Fast Five Quiz: Chronic GVHD Risk Factors and Prevention – Medscape Reference
categoriaBone Marrow Stem Cells commentoComments Off on Fast Five Quiz: Chronic GVHD Risk Factors and Prevention – Medscape Reference | dataJanuary 22nd, 2024
Read All

Could Treatments for HIV and Sickle Cell Open the Gene Therapy Floodgates? – BioSpace

By daniellenierenberg

Could Treatments for HIV and Sickle Cell Open the Gene Therapy Floodgates?  BioSpace

Originally posted here:
Could Treatments for HIV and Sickle Cell Open the Gene Therapy Floodgates? - BioSpace

To Read More: Could Treatments for HIV and Sickle Cell Open the Gene Therapy Floodgates? – BioSpace
categoriaBone Marrow Stem Cells commentoComments Off on Could Treatments for HIV and Sickle Cell Open the Gene Therapy Floodgates? – BioSpace | dataJanuary 22nd, 2024
Read All

Herbosa: Clinic under probe after skin treatments linked to womans death – Philstar.com

By daniellenierenberg

Herbosa: Clinic under probe after skin treatments linked to womans death  Philstar.com

See the article here:
Herbosa: Clinic under probe after skin treatments linked to womans death - Philstar.com

To Read More: Herbosa: Clinic under probe after skin treatments linked to womans death – Philstar.com
categoriaSkin Stem Cells commentoComments Off on Herbosa: Clinic under probe after skin treatments linked to womans death – Philstar.com | dataJanuary 22nd, 2024
Read All

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

By Dr. Matthew Watson

DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 (the “Amendment”) to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, October 29, 2021, July 11, 2022 and March 31, 2023 (the “Credit Agreement”).

Here is the original post:
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

To Read More: Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
categoriaGlobal News Feed commentoComments Off on Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility | dataJanuary 22nd, 2024
Read All

Kane Biotech Announces Special Meeting of Shareholders

By Dr. Matthew Watson

WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “Meeting”) to consider the election of Dr. Robert Huizinga as an additional director of the Company. The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course.

Original post:
Kane Biotech Announces Special Meeting of Shareholders

To Read More: Kane Biotech Announces Special Meeting of Shareholders
categoriaGlobal News Feed commentoComments Off on Kane Biotech Announces Special Meeting of Shareholders | dataJanuary 22nd, 2024
Read All

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

By Dr. Matthew Watson

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.

Read the original post:
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

To Read More: Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
categoriaGlobal News Feed commentoComments Off on Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics | dataJanuary 22nd, 2024
Read All

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children…

By Dr. Matthew Watson

REVASCOR Increases Size of Left Heart Chamber and Improves Surgical Outcomes in Children with Hypoplastic Left Heart Syndrome: Results Published in Journal of Thoracic and Cardiovascular Surgery Open

Read more from the original source:
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children...

To Read More: United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children…
categoriaGlobal News Feed commentoComments Off on United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children… | dataJanuary 22nd, 2024
Read All

Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

By Dr. Matthew Watson

Allschwil, Switzerland, January 19, 2024

Original post:
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

To Read More: Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
categoriaGlobal News Feed commentoComments Off on Cresemba® sales in Latin America trigger first sales milestone payment to Basilea | dataJanuary 22nd, 2024
Read All

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

By Dr. Matthew Watson

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates from its oral presentation at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024) in San Diego, California.

Link:
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

To Read More: ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
categoriaGlobal News Feed commentoComments Off on ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 | dataJanuary 22nd, 2024
Read All

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

By Dr. Matthew Watson

FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval

Read the original:
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

To Read More: Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
categoriaGlobal News Feed commentoComments Off on Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer | dataJanuary 22nd, 2024
Read All

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

By Dr. Matthew Watson

MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced that it will host a virtual KOL event on Thursday, January 25, 2024 at 10:00 am ET to briefly review, then discuss the topline results from the Phase IIb PORTICO study evaluating vafidemstat in Borderline Personality Disorder (BPD). To register for the event, click here.

Here is the original post:
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

To Read More: ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
categoriaGlobal News Feed commentoComments Off on ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024 | dataJanuary 22nd, 2024
Read All

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

By Dr. Matthew Watson

- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator -

See the original post:
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

To Read More: Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
categoriaGlobal News Feed commentoComments Off on Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate | dataJanuary 22nd, 2024
Read All

SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million

By Dr. Matthew Watson

TEL AVIV, Israel, Jan. 19, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it entered, as lender, into a bridge loan agreement (the "Agreement) with a leading vehicle importer company in Israel, as borrower (the "Target Company"), pursuant to which the Target Company received a bridge loan (the “Bridge Loan”) in the amount of $1.4 million, further to the previously-announced non-binding letter of intent (the “LOI”) for the Company to acquire the Target Company (the “Acquisition”).

See the original post here:
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million

To Read More: SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
categoriaGlobal News Feed commentoComments Off on SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million | dataJanuary 22nd, 2024
Read All

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced…

By Dr. Matthew Watson

Basel, January 19, 2024 – Novartis today presented data from the Phase III NETTER-2 trial showing that Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus long-acting release (LAR) octreotide reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose octreotide LAR alone1. Data were presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.

Read more:
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced...

To Read More: Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced…
categoriaGlobal News Feed commentoComments Off on Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced… | dataJanuary 22nd, 2024
Read All

Change of management at NTG Nordic Transport Group A/S

By Dr. Matthew Watson

Company announcement no. 1 – 24 19 January 2024

See the article here:
Change of management at NTG Nordic Transport Group A/S

To Read More: Change of management at NTG Nordic Transport Group A/S
categoriaGlobal News Feed commentoComments Off on Change of management at NTG Nordic Transport Group A/S | dataJanuary 22nd, 2024
Read All

Zealand Pharma major shareholder announcement: J O Hambro Capital Management

By Dr. Matthew Watson

Company announcement – No. 5 / 2024

Originally posted here:
Zealand Pharma major shareholder announcement: J O Hambro Capital Management

To Read More: Zealand Pharma major shareholder announcement: J O Hambro Capital Management
categoriaGlobal News Feed commentoComments Off on Zealand Pharma major shareholder announcement: J O Hambro Capital Management | dataJanuary 22nd, 2024
Read All

Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04

By Dr. Matthew Watson

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the reinspection of Alvotech’s facility in Iceland by the U.S. Food and Drug Administration (FDA) which started on January 10, 2024, has been concluded. Following the FDA inspection, Alvotech received a form 483 with one observation. Alvotech expects to provide the FDA with a response in the following days.

See the article here:
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04

To Read More: Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
categoriaGlobal News Feed commentoComments Off on Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 | dataJanuary 22nd, 2024
Read All

Page 10«..9101112..2030..»


Copyright :: 2024